The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
Phase 1 study suggests that intravitreous injection of 0.004mg may be lowest effective dose.
And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC.
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer
The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.
After completion of the initial bevacizumab treatment cycle, there was a significant reduction in epistaxis severity scores and RBC transfusion requirements.
However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group.
Bevacizumab (Avastin) used to treat retinopathy of prematurity (ROP) may be linked to serious disabilities such as cerebral palsy and hearing loss, according to a study published in Pediatrics.
Both linked to improvements in visual acuity; only triamcinolone tied to sustained improvement in CMT
Drugs in the Pipeline
Amgen and Allergan announced that their biosimilar candidate ABP 215 met its primary and secondary endpoints in a Phase 3 study evaluating its efficacy and safety compared with Avastin (bevacizumab) in adult patients with advanced non-squamous non-small cell lung cancer (NSCLC).